Each of Caliper’s ProfilerPro Kinase Selectivity Assay Kits contain all necessary reagents and controls for rapidly profiling up to 12 different compounds against 24 protein kinases per kit; and now ...

- Collaboration with Pfizer Yields Improved Methods for Detecting In-Cell Kinase Activity -HOPKINTON, Mass., Nov. 2, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading ...

- Collaboration with Pfizer Yields Improved Methods for Detecting In-Cell Kinase Activity -HOPKINTON, Mass., Nov. 2, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading ...

Awards. DEI Awards; Innovation Awards; Resources. Webinars; Fierce Events; Industry Events; Podcasts; Survey ...

Caliper has met or exceeded financial guidance for 13 consecutive quarters. 25% of their 2007 revenues are coming from new products with long term growth prospects on the order of 10-12% per year.

Caliper Life Sciences and DxTerity Diagnostics entered into a co-development and co-marketing collaboration that will allow researchers to perform DxTerity’s NEAT multiplex diagnostic assays on ...

Traditional kinase activity assays have used the incorporation of a radioactive 32 P or 33 P into ATP, and followed the transfer of the radioisotope to the substrate. The key to this assay is ...

Caliper Life Sciences of Hopkinton, Massachusetts, plans to buy NovaScreen Biosciences for $22 million. Caliper says the deal adds screening, profiling and assay development services and will make ...

The promiscuity of most kinase inhibitors can cause drug toxicity and complicate the interpretation of experiments. Rather than assessing kinase-compound binding, Anastassiadis et al. use ...

J.R.S. designed the p38α and cSrc constructs for labeling, developed the fluorescent-labeled kinase assay system and determined compound K d, k on and k off values.

The collaboration between Caliper and Pfizer is focused on developing cellular methods to measure the ability of a compound to inhibit kinase activity. Nine different kinase assays through this ...